-
Mashup Score: 0
Post hoc analyses from JAVELN Bladder 100 shed light on the long-term safety profile of avelumab first-line maintenance for patients with aUC.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0சிறுநீர்ப்பை புற்றுநோயின் அறிகுறிகள் என்ன? | Checkup | DR Anitha Ramesh Interview | Bladder cancer - 11 month(s) ago
சிறுநீர்ப்பை புற்றுநோயின் அறிகுறிகள் என்ன? | Checkup | DR Anitha Ramesh Interview!#bladdercancer #doctor #interview கலைஞர் செய்திகள் தொலைக்காட்சி இப்போது அனை…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
#Treatment : Surgery, radiation therapy, chemotherapy, #Immunotherapy #Avelumab #urinarybladdercancer #merck Symptoms: Blood in the urine, pain with urination . https://t.co/0W7Vd3RrVI #KalaignarSeithigal #tvshow show https://t.co/4mMmmCONf8
-
-
Mashup Score: 0
According to interim phase 2 results, GEN-001 in combination with avelumab has a significant objective response rate in patients with gastric and gastroesophageal junction adenocarcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
A study sought to learn if the number of patients initiating chemotherapy after avelumab’s approval was higher than the number before approval.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Consistent Findings of Avelumab Maintenance for Metastatic Urothelial Carcinoma Shown in Real-World Data - 1 year(s) ago
In the PATRIOT-II study, patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance had a complete response rate of 13% and a partial response (PR) rate of 68%.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Real-World Data Supports Avelumab Use for Locally Advanced, Metastatic Urothelial Carcinoma - 1 year(s) ago
Treatment with avelumab for locally advanced or metastatic urothelial carcinoma showed to be consistent in a real-world with what was previously seen in the phase 3 JAVELIN Bladder 100 trial.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Consistent Findings of Avelumab Maintenance for Metastatic Urothelial Carcinoma Shown in Real-World Data - 1 year(s) ago
In the PATRIOT-II study, patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance had a complete response rate of 13% and a partial response (PR) rate of 68%.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Jeanny B. Aragon-Ching, MD, FACP, describes the available treatment options for patients with metastatic UC who progress on avelumab maintenance.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Two drugs for the treatment of metastatic urothelial carcinoma—eftilagimod alpha and avelumab—will be examined in the phase 1 INSIGHT-005 clinical trial.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A new year means new clinical trials: The INSIGHT-005 study will examine the combination treatment of eftilagimod alpha & #avelumab for metastatic urothelial #carcinoma. The study's first patient is set to be enrolled and dosed early this year. Read more: https://t.co/UsdQpqMQP6 https://t.co/CJXXN6GrJo
-
-
Mashup Score: 0
Two drugs for the treatment of metastatic urothelial carcinoma—eftilagimod alpha and avelumab—will be examined in the phase 1 INSIGHT-005 clinical trial.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
A post hoc analysis from the JAVELIN Bladder 100 trial on #avelumab first-line maintenance for patients with advanced urothelial carcinoma was presented at #ASCO23. The safety profile of avelumab was found to be consistent with prior monotherapy studies: https://t.co/O09VvMZCTa https://t.co/MG26jrDom2